Quarterly report · Q1
4564.TEDINET S100ROVK
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥148m | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥386m | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥386m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | −¥307m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥397m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥314m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥277m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.3bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.0bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥346m | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥930m | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥913m | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-1.99 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥122,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥122,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥102m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥148m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥148m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥51m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥509,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥387,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥122,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥233m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥148m |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥148m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥122,000 |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | −¥284m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥101m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥215m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | −¥206m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 300
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes payable | Prior1YearInstant | 69380000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 34639000 | JPY |
| Other cl | Prior1YearInstant | 144835000 | JPY |
| Other cl | CurrentQuarterInstant | 17993000 | JPY |
| Current liabilities | Prior1YearInstant | 609224000 | JPY |
| Current liabilities | CurrentQuarterInstant | 298726000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 47045000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 47075000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 47045000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 47075000 | JPY |
| Liabilities | Prior1YearInstant | 656269000 | JPY |
| Liabilities | CurrentQuarterInstant | 345802000 | JPY |
| Capital stock | Prior1YearInstant | 789114000 | JPY |
| Capital stock | CurrentQuarterInstant | 1024314000 | JPY |
| Capital surplus | Prior1YearInstant | 24793617000 | JPY |
| Capital surplus | CurrentQuarterInstant | 25028817000 | JPY |
| Retained earnings | Prior1YearInstant | -24804823000 | JPY |
| Retained earnings | CurrentQuarterInstant | -25205309000 | JPY |
| Shareholders equity | Prior1YearInstant | 777908000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 847822000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 77260000 | JPY |
| Subscription rights to shares | CurrentQuarterInstant | 81925000 | JPY |
| Net assets | Prior1YearInstant | 855169000 | JPY |
| Net assets | CurrentQuarterInstant | 929747000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 1511438000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 1275549000 | JPY |
| Business revenue | Prior1YTDDuration | 385703000 | JPY |
| Business revenue | CurrentYTDDuration | 148137000 | JPY |
| Cost of sales | Prior1YTDDuration | 339261000 | JPY |
| Cost of sales | CurrentYTDDuration | 189898000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 233591000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 234467000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 120202000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 110022000 | JPY |
| Business expenses | Prior1YTDDuration | 693056000 | JPY |
| Business expenses | CurrentYTDDuration | 534388000 | JPY |
| Operating income | Prior1YTDDuration | -307352000 | JPY |
| Operating income | CurrentYTDDuration | -386251000 | JPY |
| Stock issuance cost noe | Prior1YTDDuration | － | JPY |
| Stock issuance cost noe | CurrentYTDDuration | 7609000 | JPY |
| Foreign exchange losses noe | Prior1YTDDuration | 6740000 | JPY |
| Foreign exchange losses noe | CurrentYTDDuration | 3385000 | JPY |
| Non operating expenses | Prior1YTDDuration | 6740000 | JPY |
| Non operating expenses | CurrentYTDDuration | 10995000 | JPY |
| Ordinary income | Prior1YTDDuration | -314093000 | JPY |
| Ordinary income | CurrentYTDDuration | -397246000 | JPY |
| Gain on reversal of subscription rights to shares ei | Prior1YTDDuration | 37755000 | JPY |
| Gain on reversal of subscription rights to shares ei | CurrentYTDDuration | － | JPY |
| Extraordinary income | Prior1YTDDuration | 37755000 | JPY |
| Extraordinary income | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |